Meridian Bioscience, Inc. (VIVO) Misses Q2 EPS by 4c; Cuts FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $5.60 -4.6%
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC: -84.07M
Today's EPS Names:
MAYS, CRMT, REPL, More
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC: -84.07M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.17, $0.04 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $40.05 million versus the consensus estimate of $43.13 million.
Meridian Bioscience, Inc. sees FY2011 EPS of $0.68-$0.71, versus prior guidance of $0.77-$0.82 and the consensus of $0.79.
Meridian Bioscience, Inc. sees FY2011 EPS of $0.68-$0.71, versus prior guidance of $0.77-$0.82 and the consensus of $0.79.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
